• Follow
  • Follow
  • Follow
  • About
    • About
    • Management Team
    • Board of Directors
  • Our Businesses
    • Active Ingredients (Ceapro)
    • Oral Thin Film (Nualtis)
  • Technologies
  • Investors and News
    • Press Releases
    • Events & Presentations
    • Investor Contacts
    • Stock Information
    • Financial Filings
      • SEC Filings
      • SEDAR
    • Governance
      • Corporate Governance
      • Board Committees
      • Board Diversity Matrix
      • Clawback Policy
      • Annual Reports
    • Email Alerts
  • Contact

Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program

by jtcir-auto | Jun 13, 2022 | Press Releases

– Company advancing AIM Biologicals development program as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder (“NMOSD”) – Positive results presented at the 13th International Congress on Autoimmunity being held...

Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference

by jtcir-auto | Jun 9, 2022 | Press Releases

Live video webcast on Wednesday, June 15th at 12:30 PM ET TORONTO, ONTARIO, June 09, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing...

Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (macimorelin) for Diagnosing Adult Growth Hormone Deficiency

by jtcir-auto | May 25, 2022 | Press Releases

TORONTO, ONTARIO, May 25, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of...

Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference

by jtcir-auto | May 18, 2022 | Press Releases

TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of...

Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation

by jtcir-auto | May 16, 2022 | Press Releases

TORONTO, ON, May 16, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today...
« Older Entries
Next Entries »

Recent Posts

  • COSCIENS Biopharma Inc. Reports Q3 2026 Results and Provides Update On Convertible Debenture Offering
  • COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS ACQUIRES NUALTIS CORP.
  • COSCIENS Biopharma Inc. Reports Q2 2026 Results

Recent Comments

No comments to show.
Latest News:

Stock Info

TSX:

 

 

Sign Up For Alerts

Click Here and Stay Up To Date With Cosciens News and Events

 

Contact Us

© 2026 COSCIENS BIOPHARMA   All Rights Reserved   Terms and Conditions  Privacy Policy

  • Follow
  • Follow
  • Follow